Fiche publication
Date publication
juillet 2025
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Jairath V, D'Haens G, Sands BE, Travis S, Chaparro M, Peyrin-Biroulet L, Chen MH, Dubinsky M, Ferrante M, Schreiber S, McGinnis K, Vadhariya A, Appelmans S, Lin Z, Yu G, Protic M, Moses R, Ghosh S
Lien Pubmed
Résumé
Bowel urgency (BU) is an under-recognized and debilitating symptom of Crohn's disease (CD). Mirikizumab, an interleukin-23p19 inhibitor, is efficacious for BU resolution in ulcerative colitis. We evaluated the efficacy of mirikizumab in achieving early BU response and remission among participants with CD enrolled in the Phase 3 VIVID-1 trial. The associations of disease characteristics with baseline BU and BU resolution were explored.
Mots clés
Bowel urgency, Crohn’s disease, Urgency NRS, mirikizumab
Référence
Clin Gastroenterol Hepatol. 2025 07 14;:
